This analysis was performed by examining co-immunoprecipitation of Bim with each of the antiapoptotic proteins, as described in Figure 2A. Our analysis with multiple independent CLL patient samples consistently demonstrated that higher levels of Bim were sequestered with Mcl-1 and Bcl-xL when cells were treated with the Bcl-2 inhibitor VEN, whereas the Bcl-2 interaction with Bim was reduced. This evidence concerns the gene BCL2L11 and B-cell chronic lymphocytic leukemia.